{Reference Type}: Journal Article
{Title}: Dendritic Cells: A Bridge between Tolerance Induction and Cancer Development in Transplantation Setting.
{Author}: Troise D;Infante B;Mercuri S;Catalano V;Ranieri E;Stallone G;
{Journal}: Biomedicines
{Volume}: 12
{Issue}: 6
{Year}: 2024 Jun 3
{Factor}: 4.757
{DOI}: 10.3390/biomedicines12061240
{Abstract}: Dendritic cells (DCs) are a heterogeneous group of antigen-presenting cells crucial for fostering allograft tolerance while simultaneously supporting host defense against infections and cancer. Within the tumor microenvironment, DCs can either mount an immune response against cancer cells or foster immunotolerance, presenting a dual role. In immunocompromised individuals, posttransplant malignancies pose a significant health concern, with DCs serving as vital players in immune responses against cancer cells. Both recipient- and donor-derived DCs play a critical role in the rejection process, infiltrating the transplanted organ and sustaining T-cell responses. The use of immunosuppressive drugs represents the predominant approach to control this immunological barrier in transplanted organs. Evidence has shed light on the immunopharmacology of these drugs and novel strategies for manipulating DCs to promote allograft survival. Therefore, comprehending the mechanisms underlying this intricate microenvironment and the effects of immunosuppressive therapy on DCs is crucial for developing targeted therapies to reduce graft failure rates. This review will delve into the fundamental immunobiology of DCs and provide a detailed exploration of their clinical significance concerning alloimmune responses and posttransplant malignancies.